.svg){kind=small}
Where to Buy
Quality Drugs is stocked at 72 licensed dispensaries across Oregon, with the deepest coverage in Portland, Medford, Bend, Tigard, and Cottage Grove. Search by ZIP code or city below to find the closest one, or filter by product type if you are after a specific format.
Market Insights Snapshot
In July 2026, Quality Drugs operated as a single-category brand with Edible representing 100.0% of sales, posting year-over-year growth of 23.0% and month-over-month expansion of 0.7%. Average price declined 9.8% YoY while the brand’s 24-month sales trajectory rose 91.1%, indicating unit gains offsetting price compression. Within Oregon Edibles, the brand held rank 9, and the combination of rank stability and a 23.0% YoY lift suggests mix depth within Edible rather than diversification pressure. The pattern implies Quality Drugs is leaning into price-accessible Edibles to capture incremental share through volume without cross-category dilution.
The convergence of a 9.8% YoY price decline and a 0.7% MoM sales uptick in July 2026 points to elastic demand in Edibles, with the rank 9 position in Oregon consistent with volume-led positioning rather than premium pricing. With 100.0% category concentration and 23.0% YoY sales growth, the brand’s growth engine is unit throughput, not mix expansion, which raises sensitivity to promotional cadence and retail placement. The pattern implies Quality Drugs’ current stance is to defend and gradually widen Edible share via affordability, accepting tighter price ceilings to sustain rank while banking on continued 24-month momentum of 91.1% to maintain visibility.
Competitive Landscape
Quality Drugs sits at rank #9 in OR Edible for July 2026, unchanged YoY from #9, with a peak at #8 in April 2025 indicating a one-position pullback since that high and a flat three-month trend holding at #9; meanwhile, Wyld holds #1 with a +2.5% YoY sales change versus Drops at #3 with a -5.3% YoY decline, and Mule Extracts advanced sales by +7.5% while Good Tide contracted -9.8%, signaling a bifurcated competitive field; the flat #9 YoY and three-month hold at #9 imply Quality Drugs is maintaining share against mixed competitor momentum but requires a catalyst to reattain the #8 peak.
Notable Products
Watermelon Gummy (100mg) posted the steepest decline at -23.8% MoM while sitting at rank 3, and Lifted Lime Gummy (100mg) fell even harder at -26.2% MoM at rank 6, indicating flavor-specific softness within core Edibles. In contrast, Assorted Caramels 10-Pack (100mg) climbed 30.6% MoM to rank 4 and CBD/CBN/THC 1:1:1 Cherry Bomb Remix Gumdrops 10-Pack (100mg CBD, 100mg CBN, 100mg THC) rose 13.3% MoM at rank 8, while the THC/CBD 2:1 Radiant Raspberry Gummy (100mg THC, 50mg CBD) held rank 1 with an 8.2% MoM uptick and $20,363 in July 2026 sales. Eight of the top ten are Edible SKUs, and three of the top four carry either mixed-cannabinoid ratios or multi-pack formats, pointing to a shift toward differentiated formulations over single-flavor gummies.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
